Developing treatments for serious infections caused by dangerous pathogens
Official title: Antiviral & Antimicrobial Countermeasures Discovery and Development Core
Funded at University of Tennessee Health Sci Ctr · NIH-10910184 · Data updated 2026-11-12
This study is looking for new medicines to help treat serious infections caused by tough germs, using special technology to see how these drugs work, and it's all done in a safe lab to help find better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | August 18, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $1,295,544 |
| NIH project number | 5UC7AI180313-02 |
| Project ID | NIH-10910184 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of infections from biosafety level 2 or 3 pathogens, such as those with compromised immune systems or specific health conditions.
✕Less likely to help
Patients with infections caused by low-risk pathogens or those not requiring specialized antiviral or antimicrobial treatments may not benefit from this research.
What this research studies
This research focuses on discovering and developing new antiviral and antimicrobial treatments for serious infections caused by high-risk pathogens. It utilizes advanced technologies for screening potential drugs, imaging infected tissues, and analyzing drug effects on pathogens. The research is conducted in a specialized laboratory designed to safely handle these dangerous pathogens, ensuring that findings can lead to effective therapies for patients. By studying how drugs interact with infections, the project aims to improve treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new and effective treatments for infections caused by dangerous pathogens, improving patient health outcomes.
How similar studies have gone: Previous research has shown success in developing treatments for similar high-risk pathogens using advanced drug discovery methods, indicating a promising approach.
Where this research is happening
-
University of Tennessee Health Sci Ctr
Memphis, United States Active
Researchers
- Principal investigator: Jonsson, Colleen B — University of Tennessee Health Sci Ctr
- Study coordinator: Jonsson, Colleen B
Related research
Other NIH-funded projects on the same topics.
-
EP2 blockers to protect the brain after a stroke
Aims to test brain-permeable EP2 antagonists to reduce damage after ischemic stroke and improve recovery.
-
HIV drugs may also stop a dangerous fungus from growing
A cancer/antifungal researcher is exploring whether HIV medicines can help treat cryptococcal infections in people with HIV/AIDS.
-
Profiling immune cells to find early inflammation clues in kids with obesity and insulin resistance
This project looks at how immune cells in children with obesity may show early inflammatory changes linked to insulin resistance.
-
Targeted inhibitors to block a key enzyme and fight metastatic triple-negative breast cancer
A new drug candidate aimed at a specific enzyme in cancer cells is being developed to stop the spread of metastatic triple-negative breast cancer.
-
New fungal partner targets to curb Aspergillus infection in vulnerable patients
A NIH-funded project is exploring how the fungus Aspergillus fumigatus grows and causes serious infections in people with weakened immune systems, with the aim of finding new ways to stop it.
-
Epigenetic control of aging heart function
A scientist at a university is studying how aging changes heart function and whether a specific gene, KDM6A, influences this process to uncover ways to prevent or treat aging-related heart problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.